MENU

Fox Chase Cancer Center News

A higher-volume facility to provide patients with more experience, expertise, and access to resources.
September 27, 2019

Studies Find Patients Treated at Higher-Volume Cancer Facilities Tend to Live Longer

PHILADELPHIA (September 27, 2019) – These results underscore the ability of a higher-volume facility to provide patients with more experience, expertise, and access to resources.

It is hoped the novel and collaborative approach among the researchers will lead to a better way to prevent or circumvent melanoma therapy resistance in aging cells.
September 23, 2019

Researcher Receives NCI Grant to Investigate Link Between Cell Aging, Melanoma

PHILADELPHIA (September 23, 2019) – Edna Cukierman, PhD, was awarded the grant from the National Institutes of Health/National Cancer Institute to begin research on better understanding the deterioration of collagen integrity via cellular aging and its role in melanoma metastasis.

The median time to cranial neuropathy was more than seven years, with some patients developing cranial neuropathy more than 10 years later.
September 23, 2019

Radiation-Induced Cranial Neuropathy Occurred Up to 10 Years After Head and Neck Cancer Treatment

PHILADELPHIA (September 23, 2019) – Of the 112 patients examined, 14 percent developed at least one cranial neuropathy. The median time was more than seven years, with some patients developing it more than 10 years later.

Cosmesis was rated as good in 81 percent of trials of conventional excision, 74.6 percent of trials of EBRT, and 97.6 percent of trials of brachytherapy.
September 20, 2019

Cosmetic Satisfaction Similar for Radiation, Surgical Treatments of Non-Melanoma Skin Cancers

PHILADELPHIA (September 20, 2019) – Many of the most common treatment modalities for localized non-melanoma skin cancers resulted in similar cosmetic outcome and local control one year after treatment, according to a new study from researchers at Fox Chase Cancer Center.

September 15, 2019

Patient-Reported Quality of Life May Guide Treatment Decisions for Lower-Risk Prostate Cancer

CHICAGO (September 15, 2019) – New research from Fox Chase Cancer Center may help guide men with prostate cancer in selecting the appropriate type of short course radiation therapy to treat their disease.

“We wanted to investigate the relationship between severe lymphopenia and poor survival, and if they were linked, potentially alter treatment regimens.”
September 15, 2019

Severe Lymphopenia Linked With Worse Outcomes After Chemoradiation for Esophageal Cancer

CHICAGO (September 15, 2019) – Patients with esophageal cancer who experienced severe lymphopenia after undergoing chemoradiation were more likely to have their disease recur and were at greater risk for death, according to a new study from researchers at Fox Chase Cancer Center.

Fox Chase-Temple University Hospital Bone Marrow Transplant Program
September 13, 2019

Fox Chase Cancer Center Welcomes Michael Jay Styler

PHILADELPHIA (September 13, 2019) – Fox Chase Cancer Center hired Michael Jay Styler, MD, for the Department of Hematology/Oncology as an associate professor in the Bone Marrow Transplant Program.

September 11, 2019

Connolly Wins Rollman Award for Ovarian Cancer Research

Dr. Connolly is currently researching a subtype of ovarian cancer, high-grade serous carcinoma, in mouse models to understand why not all ovarian cancer arises in the ovary. Another project Connolly explores how a specific tool antibody may be developed into a therapeutic drug to kill ovarian cancer cells.Dr. Connolly is currently researching a subtype of ovarian cancer, high-grade serous carcinoma, in mouse models to understand why not all ovarian cancer arises in the ovary. Another project Connolly explores how a specific tool antibody may be developed into a therapeutic drug to kill ovarian cancer cells.

Pages

Connect with Fox Chase